• Daniel Halpern

      Chief Executive Officer & Director

      Daniel Halpern brings over 30 years of international experience building, growing, financing and investing in global healthcare and technology companies. Dan provides strategy, investment and operations support for emerging growth companies.

      He currently serves as President of Healthcare Investors, LLC, a business development and investment company, Advisory Board Member of Breast-Med, Inc., and board member and co-founder of Phyzhon Health, fka Vascular Imaging Corporation, an early-stage interventional medical device company.

      Dan is actively engaged in developing new technology-based companies. Portfolio companies are primarily involved in applications of medical imaging and image-guided therapeutics.

      Previously, Dan served as President and co-founder of Sunlight Research, LLC , a patent claims analysis and intellectual property market research firm, and he served in senior management roles with Financing for Science International, an equipment leasing company acquired by Finova Group Inc. (NYSE: FNV); Elscint, Inc. (NYSE: ELT), a medical diagnostic imaging equipment manufacturer, whose medical imaging businesses were acquired by GE Medical and Philips/Marconi; and Elron Electronic Industries Ltd. (TASE: ELRN), an international industrial holding company headquartered in Israel, where he served as U.S. General Manager.

      Dan holds an MBA degree from New York University's Stern School of Business and a B.A. degree from the University of Michigan.

      Ivan Ma

      Chief Product Officer

      Ivan Ma brings over 15 year of experience in the medical device industry in various leadership and design positions spanning a wide range of medical devices; from single use to complex surgical hardware. Most recently he was a manager of robotic systems at Verb Surgical, at Verily (an Alphabet company) and Ethicon (a Johnson and Johnson company) joint venture, where led various teams toward critical program milestones starting from the company’s inception in 2016. Prior to that, Ivan had leading and engineering roles in the companies with a broad range of technologies such as: intracardiac pacemaker, therapeutic hypothermia, deep brain stimulation, cryogenic tissue ablation, a cell phone enabled otoscope, and a white blood cell imaging system. Ivan has specialized in bringing early phase projects through development in preparation for FDA submission and human use. Ivan holds a B.S. in mechanical engineering from Boston University.